Hyderabad, July 29
Hetero Labs, a part of Hetero group, on Wednesday introduced the launch of generic Favipiravir in India beneath the model title ‘Favivir.’
According to a press launch issued by the city-based drug maker, Hetero has been granted the manufacturing and advertising and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used within the remedy of COVID-19.
It is an oral antiviral treatment that has demonstrated optimistic scientific outcomes.
Favivir improves remedy accessibility to a big quantity of COVID-19 affected person inhabitants, which often sustains delicate to average signs.
Hetero’s Favivir is priced at Rs 59 per pill and is marketed and distributed by Hetero Healthcare Ltd.
The product is obtainable from July 29 in any respect retail medical shops and hospital pharmacies throughout the nation and might be bought solely on prescription, it stated.
Backed by robust vertical integration capabilities, the drug is being manufactured on the firm’s world-class formulation facility in India, which has been authorised by stringent international regulatory authorities corresponding to USFDA and the EU, amongst others, based on the discharge. –PTI